BGA
BCRX icon

Belmont Global Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Belmont Global Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$127K – 126
2014
Q2 		$127K Hold
10,000
– – 0.09% 123
2014
Q1 		$106K Buy
+10,000
New +$107K 0.09% 111

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Belmont Global Advisors's BCRX Position: Q3 2014 in Review

Belmont Global Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2014, closing a stake of 10,000 shares — an estimated $127K sold.

Belmont Global Advisors first reported a position in BCRX in Q1 2014 and held it in 2 quarters. The position peaked at $127K in Q2 2014. 102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

  • Belmont Global Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Belmont Global Advisors sold 10,000 BioCryst Pharmaceuticals shares in Q3 2014, an estimated $127K.
  • Belmont Global Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Belmont Global Advisors's BioCryst Pharmaceuticals position peaked at $127K in Q2 2014.
  • 102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on Belmont Global Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.